International Plc Endo Net Worth

The estimated Net Worth of International Plc Endo is at least 8.85 千$ dollars as of 2 December 2020. International Endo owns over 7,344,955 units of Biospecifics Technologies stock worth over 8,853$ and over the last 4 years International sold BSTC stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

International Endo BSTC stock SEC Form 4 insiders trading

International has made over 1 trades of the Biospecifics Technologies stock since 2020, according to the Form 4 filled with the SEC. Most recently International bought 7,344,955 units of BSTC stock worth 650,028,518$ on 2 December 2020.

The largest trade International's ever made was buying 7,344,955 units of Biospecifics Technologies stock on 2 December 2020 worth over 650,028,518$. On average, International trades about 7,344,955 units every 0 days since 2020. As of 2 December 2020 International still owns at least 100 units of Biospecifics Technologies stock.

You can see the complete history of International Endo stock trades at the bottom of the page.

What's International Endo's mailing address?

International's mailing address filed with the SEC is FIRST FLOOR, MINERVA HOUSE,, SIMMONSCOURT ROAD, BALLSBRIDGE, DUBLIN 4, L2, .

Insiders trading at Biospecifics Technologies

Over the last 33 years, insiders at Biospecifics Technologies have traded over 67,860,045$ worth of Biospecifics Technologies stock and bought 7,761,661 units worth 656,708,120$ . The most active insiders traders include Capital Management, Llc Kol...、International Plc Endo、Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of 6,538,649$. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth 650,028,518$.

What does Biospecifics Technologies do?

Complete history of International Endo stock trades at Biospecifics Technologies

Biospecifics Technologies executives and stock owners

Biospecifics Technologies executives and other stock owners filed with the SEC include:

• Jennifer Chao,
  Independent Chairman of the Board
• Michael Schamroth,
  Independent Director
• Paul Gitman,
  Independent Director
• Mark Wegman,
  Director
• Toby Wegman,
  Director
• Sarah McCabe,
  Stern Investor Relations
• Michael Sherman,
  Independent Director
• Corey Fishman,
  Independent Director
• Alex Monteith,
  Senior Vice President and Chief Business Officer
• Patrick Hutchison,
  Chief Financial Officer
• Joseph Truitt,
  Chief Executive Officer, Director
• Jeffrey Kenneth Vogel,
  
• Jyrki Mattila,
  Director
• Thomas Wegman,
  President
• Of Edwin H. Wegman Estate,
  10% owner
• Patrick M Caldwell,
  Principal Financial Officer
• Partners Lp Bio,
  10% owner
• Albert Horcher,
  
• Lawrence Dobroff,
  CFO
• Max Link,
  Director
• Henry Morgan,
  Director
• George M Gould,
  Director
• Matthew Geller,
  Director
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• Capital Management, Llcaldr...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• J Kevin Buchi,
  Chief Executive Officer
• International Plc Endo,
  10% owner